- STRO -0.78%
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
Yahoo Finance · 2 weeks ago
Open | 3.7900 |
High | 3.8800 |
Low | 3.7450 |
Mkt Cap | 312.45M |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 3.8500 |
52 Wk. Low | 2.0100 |
52 Wk. High | 6.1300 |
Related stocks
Company
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 13.01M | 2.60% ▲ |
Net Income | -58.21M | - |
Diluted EPS | -0.95 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | -$0.79 | - |
Q1 2024 | -$0.92 | -$0.95 |
Q4 2023 | -$0.82 | $0.52 |
S&P FuturesES=F | 5,390.75+6.75 (+0.13%) |
Dow FuturesYM=F | 38,831.00+37.00 (+0.10%) |
Nasdaq FuturesNQ=F | 19,272.75+30.50 (+0.16%) |
123.88-0.50% | |
33.80+11.04% | |
30.49+22.80% |